Searched for
PRIMARY BILIARY CHOLANGITIS
Stocks in news: RIL, Coal India, IDFC First Bank, Zydus Life, ONGCMarkets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
- New study finds one blood type faces a much higher risk of deadly liver diseasePeople with blood type A may have a higher chance of autoimmune liver disease, while type B seems safer. Autoimmune liver problems happen w...
- Zydus Lifesciences to raise Rs 5,000 cr via equity; Q2 profit up 38%Zydus Lifesciences plans to raise Rs 5,000 crore via share sales. This move aims to reduce debt and boost future expansion. Funds will supp...
- Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS...
- Zydus eyes M&A, licensing to build its US specialty businessZydus Lifesciences is exploring mergers, acquisitions, and licensing to bolster its specialty portfolio in the US, particularly for the pot...
- Zydus aims to launch first new drug in US by early 2026Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition o...
- Cadila Healthcare Q1 results: Net profit rises 29% to Rs 587 crConsolidated total revenue from operations stood at Rs 4,025.4 crore for the quarter under consideration against Rs 3,514.6 crore for the s...
- European Medicines Agency grants Orphan Drug Designation to Zydus Cadila's Saroglitazar MgOrphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or ch...
- USFDA grants orphan drug designation to Zydus Cadila's Saroglitazar MgZydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, includ...
- Zydus Cadila gets USFDA Fast Track Designation for SaroglitazarDrug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug c...
- Your body's immunity can damage your liver: Watch out for these signsAutoimmune liver disease can be transmitted genetically or is caused because of some reactions wherein the liver cells are recognised as in...
- Zydus gets USFDA nod for phase II trials of liver drugThis development underlines the group's commitment to bridging unmet healthcare needs with innovative therapies.
Load More
